[1]邵毅.国际干眼新共识（TFOS DEWS Ⅱ）解读[J].眼科新进展,2018,38(1):001-12.[doi:10.13389/j.cnki.rao.2018.0001]
　SHAO Yi.Interpretation of TFOS DEWS Ⅱ[J].Recent Advances in Ophthalmology,2018,38(1):001-12.[doi:10.13389/j.cnki.rao.2018.0001]
点击复制

国际干眼新共识（TFOS DEWS Ⅱ）解读/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
38卷
期数:
2018年1期
页码:
001-12
栏目:
述评
出版日期:
2018-01-05

文章信息/Info

Title:
Interpretation of TFOS DEWS Ⅱ
作者:
邵毅
330006　江西省南昌市，南昌大学第一附属医院眼科
Author(s):
SHAO Yi
Department of Ophthalmology，the First Affiliated Hospital of Nanchang University，Nanchang 330006，Jiangxi Province，China
关键词:
干眼; 国际泪膜和眼表协会; 干眼疾病工作组第二次会议
Keywords:
dry eye disease; the Tear Film &;  Ocular Surface Society; TFOS Dry Eye Workshop Ⅱ
分类号:
R77
DOI:
10.13389/j.cnki.rao.2018.0001
文献标志码:
A
摘要:
国际泪膜和眼表协会（ the Tear Film & Ocular Surface Society，TFOS）干眼疾病工作组第二次会议（TFOS Dry Eye Workshop Ⅱ，TFOS DEWS Ⅱ）对干眼（dry eye disease，DED）的定义、分类、诊断和治疗等有了新的定义和观点，本文将对此次会议产生的共识进行全面解读。
Abstract:
The novel definitions and views on the definition，classification，diagnosis and treatment of dry eye disease (DED) have been proposed at the Tear Film & Ocular Surface Society Dry Eye Workshop Ⅱ (TFOS DEWS Ⅱ) conference，and this article will give an interpretation of the contents from the conference.

参考文献/References:

［1］　NELSON JD，CRAIG JP，AKPEK EK，AZAR DT，BELMONTE C，BRON AJ，et al.TFOS DEWS Ⅱ introduction［J］.Ocul Surf，2017，15（3）：269-275.
［2］　WILLCOX MDP，ARGüESO P，GEORGIEV G，HOLOPAINEN J，LAURIE G，MILLAR T，et al.TFOS DEWS Ⅱ Tear Film report［J］.Ocul Surf，2017，15（3）：366-403.
［3］　LEMP MA，BAUDOUIN C，BAUM J，DOGRU M，FOUIKS GN，KINOSHITA S，et al.The definition and classification of dry eye disease：report of the Definition and Classification Subcommittee of the International Dry Eye Work Shop(2007)［J］.Ocul Surf，2007，5(2)：75-92.
［4］　BAUDOUIN C，MESSMER EM，ARAGONA P，GEERLING G，AKOVA YA，BENíTEZ-DEL-CASTILLO J，et al.Revisiting the vicious circle of dry eye disease：a focus on the pathophysiology of meibomian gland dysfunction［J］.Br J Ophthalmol，2016，100(3)：300-306.
［5］　SHIMAZAKI J，GOTO E，ONO M，SHIMMURA S，TSUBOTA K.Meibomian gland dysfunction in patients with Sjgren syndrome［J］.Ophthalmology，1998，105(8)：1485-1488.
［6］　BELMONTE C，NICHOLS JJ，COX SM，BROCK JA，BEGLEY CG，BEREITER DA，et al.TFOS DEWS Ⅱ pain and sensation report［J］.Ocul Surf，2017，15(3)：404-437.
［7］　GOMES JAP，AZAR DT，BAUDOUIN C，EFRON N，HIRAYAMA M，HORWATH-WINTER J，et al.TFOS DEWS Ⅱ Iatrogenic report［J］.Ocul Surf，2017，15(3)：511-538.
［8］　LEMP MA，CREWS LA，BRON AJ，FOULKS GN，SULLIVAN BD.Distribution of aqueousdeficient and evaporative dry eye in a clinic-based patient cohort：a retrospective study［J］.Cornea，2012，31(5)：472-478.
［9］　SMITH JA，BEGLEY G，NICHOL K，SCHEIN O，ALBENZ J，CAFFERY B，et al.The epidemiology of dry eye disease：report of the epidemiology subcommittee of the international dry eye WorkShop［J］.Ocul Surf，2007，5(2)：93-107.
［10］　WOLFFSOHN JS，ARITA R，CHALMERS R，DJALILIAN A，DOGRU M，DUMBLETON K,et al.TFOS DEWS Ⅱ Diagnostic Methodology report［J］.Ocul Surf，2017，15(3)：539-574.
［11］　BARTLETT JD，KEITH MS，SUDHARSHAN L，SNEDECOR SJ.Associations between signs and symptoms of dry eye disease：a systematic review［J］.Clin Ophthalmol，2015，9：1719-1730.
［12］　GUO B，LU P，CHEN XM，ZHANG WF，CHEN RT.Prevalence of dry eye disease in Mongolians at high altitude in China：the Henan eye study［J］.Ophthalmic Epidemiol，2010，17(4)：234-241.
［13］　TONG L，SAW SM，LAMOUREUX EL，WANG JJ，ROSMAN M，TAN DT，et al.A questionnaire-based assessment of symptoms associated with tear film dysfunction and lid margin disease in an Asian population［J］.Ophthalmic Epidemiol，2009，16(1)：31-37.
［14］　UCHINO M，SCHAUMBERG DA，DOGRU M，UCHINO Y，FU-KAQAWA K，SHIMMURA S，et al.Prevalence of dry eye disease among Japanese visual display terminal users［J］.Ophthalmology，2008，115(11)：1982-1988.
［15］　TAN LL，MORGAN P，CAI ZQ，STRAUGHAN RA.Prevalence of and risk factors for symptomatic dry eye disease in Singapore［J］.Clin Exp Optomet，2015，98(1)：45-53.
［16］　VISO E，RORDRIGUEZ-ARES MT，ABELENDA D，OUBINA B，GUDE F.Prevalence of asymptomatic and symptomatic meibomian gland dysfunction in the general population of Spain［J］.Invest Ophthalmol Vis Sci，2012，53(6)：2601-2606.
［17］　LIEW MS，ZHANG M，KIM E，AKPEK EK.Prevalence and predictors of Sjogren’s syndrome in a prospective cohort of patients with aqueous-deficient dry eye［J］.Br J Ophthalmol，2012，96(12)：1498-1503.
［18］　VEHOF J，HYSI PG，HAMMOND CJ.A metabolome-wide study of dry eye disease reveals serum androgens as biomarkers［J］.Ophthalmology，2017，124(4)：505-511.
［19］　IVANIR Y，SHIMONI A，EZRA-NIMNI O，BAREQUET IS.Prevalence of dry eye syn-drome after allogeneic hematopoietic stem cell transplantation［J］.Cornea，2013，32(5)：97-101.
［20］　UCHINO M，UCHINO Y，DOGRU M，KAWASHIMA M，YOKOI N，KOMURO A，et al.Dry eye disease and work productivity loss in visual display users：the Osaka study［J］.Am J Ophthalmol，2014，157(2)：294-300.
［21］　SCHAUMBERG DA，SULLIVAN DA，DANA MR.Epidemiology of dry eye syndrome［J］.Adv Exp Med Biol，2002，506：989-998.
［22］　MOSS SE，KLEIN R，KLEIN BE.Prevalence of and risk factors for dry eye syndrome［J］.Arch Ophthalmol，2000，118(9)：1264-1268.
［23］　SULLIVAN DA，ROCHA EM，ARAGONA P，CLAYTON JA，DING J，GOLEBIOWSKI B.TFOS DEWS Ⅱ sex，gender，and hormones report［J］.Ocul Surf，2017，15(3)：284-333.
［24］　ECKSTEIN AK，FINKENRATH A，HEILIGENHAUS A，RENZING K，ESSER J，KRUGER C，et al.Dry eye syndrome in thyroid-associated ophthalmopathy：lacrimal expression of TSH receptor suggests involvement of TSHR-specific autoantibodies［J］.Acta Ophthalmol Scand，2004，82(3)：291-297.
［25］　IMBERT Y，FOULKS GN，BERNNAN MD，JUMBLATT MM，JOHN G，SHAH HA，et al.MUC1 and estrogen receptor alpha gene polymorphisms in dry eye patients［J］.Exp Eye Res，2009，88(3)：334-88338.
［26］　SUZUKI T，SULLIVAN BD，LIU M，SCHIRRA F，RICHARDS SM，YAMAGAMIAN H，et al.Estrogen and progesterone effects on the morphology of the mouse meibomian gland［J］.Adv Exp Med Biol，2002，506：483-488.
［27］　ZYLBERBERG C，SEAMON V，PONOMAREVA O，VELLALA K，DEIGHAN M，AZZAROLO AM，et al.Estrogen up-regulation of metalloproteinase-2 and -9 expression in rabbit lacrimal glands［J］.Exp Eye Res，2007，84(5)：960-972.
［28］　SEAMON V，VELLALA K，ZYLBERBERG C，PONAMAREVA O，AZZAROLO AM.Sex hormone regulation of tear lipocalin in the rabbit lacrimal gland［J］.Exp Eye Res，2008，87(3)：184-190.
［29］　XU J，DISTECHE CM.Sex differences in brain expression of X- and Y-linked genes［J］.Brain Res，2006，1126：50-55.
［30］　LIU K，KURIEN BT，ZIMMERMAN SL，KAUFMAN KM，TAFT DH，KOTTYAN LC，et al.X chromosome dose and sex bias in autoimmune diseases［J］.Arthritis Rheumatol，2016，68(5)：1290-1300.
［31］　SCHAUMBERG DA，NCHINO M，CHRISTEN WG，SEMBA RD，BURING JE，LI JZ，et al.Patient reported differences in dry eye disease between men and women：impact，management，and patient satisfaction［J］.PLoS One，2013，8(9)：e76121.
［32］　OBATA H，YAMAMOTO S，HORIUCHI H，MACHINAMI R.Histopathologic study of human lacrimal gland.Statistical analysis with special reference to aging［J］.Ophthalmology，1995，102(4)：678-686.
［33］　ALABAS OA，TRSHANI OA，TABASAN G，JOHNSON MI.Gender role affects experimental pain responses：a systematic review with meta-analysis［J］.Eur J Pain，2012，16(9)：1211-1223.
［34］　CLAYTON JA，DAVIS AF.Sex/gender disparities and women’s eye health［J］.Curr Eye Res，2015，40(2)：102-109.
［35］　BAUDOUIN C，ARAGONA P，MESSMER EM，TOMLINSON A，CALONGE M，BOBORIDIS KG，et al.Role of hyperosmolarity in the pathogenesis and management of dryeye disease：proceedings of the OCEAN group meeting［J］.Ocul Surf，2013，11(1)：246-258.
［36］　DE PAIVA CS，CORRALES RM，VILLARREAL AL，FARLEY WJ，LI DQ，STERN ME，et al.Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression，MAPK activation in the corneal epithelium in experimental dry eye［J］.Exp Eye Res，2006，83(3)：526-535.
［37］　YEH S，SONG XJ，FARLEY W，LI DQ，STERN ME，PFLUGFELDER SC.Apoptosis of ocular surface cells in experimentally induced dry eye［J］.Invest Ophthalmol Vis Sci，2003，44(1)：124-129.
［38］　CAI K，WEI R.Interleukin-7 expression in tears and orbital tissues of patients with Graves’ ophthalmopathy［J］.Endocrine，2013，44(1)：140-144.
［39］　RICCIUTO J，HEIMER SR，GILMORE MS，ARGUESO P.Cell surface O-glycans limit Staphylococcus aureus adherence to corneal epithelial cells［J］.Infect Immun，2008，76(11)：5215-5220.
［40］　ARGUESO P，GIPSON IK.Epithelial mucins of the ocular surface：structure，biosynthesis and function［J］.Exp Eye Res，2001，73(3)：281-289.
［41］　MANTELLI F，ARGUESO P.Functions of ocular surface mucins in health and disease［J］.Curr Opin Allergy Clin Immunol，2008，8(5)：477-483.
［42］　DE PAIVA CS，RAINCE JK，MCCLELLAN AJ，SHANMUGAM KP，PANGELINAN SB，VOLPE EA，et al.Homeostatic control of conjunctival mucosal goblet cells by NKT-derived IL-13［J］.Mucosal Immunol，2011，4(4)：397-408.
［43］　BAUDOUIN C.A new approach for better comprehension of diseases of the ocular surface［J］.J Fr Ophtalmol，2007，30(3)：239-246.
［44］　FOULKS GN.DEWS report:Amission completedJ］.Ocul Surf，2007，5(2)：65-66.
［45］　KRENZER KL，CERMAK JM，TOLLS DB，PAPAS AS，DANA MR，SULLIVAN DA.Comparative signs and symptoms of dry eye in primary and secondary Sjgren’s syndrome and meibomian gland disease［J］.Investig Ophthalmol Vis Sci，2000，40(4)：S542.
［46］　BAUDOUIN C，MESSMER EM，ARAGONAJ P，GEERLING G，AKOVA YA，BENITEZ-DELCASTILLO J，et al.Revisiting the vicious circle of dry eye disease：a focus on the pathophysiology of meibomian gland dysfunction［J］.Br J Ophthalmol，2016，100(3)：300-306.
［47］　BEGLEY C，SIMPSON T，LIU H，SALVO E，WU Z，BRADLEY A，et al.Quantitative analysis of tear film fluorescence and discomfort during tear film instability and thinning［J］.Invest Ophthalmol Vis Sci，2013，54(4)：2645-2653.
［48］　TODA I，ASANO-KATO N，KOMAI-HORI Y，TSUBOTA K.Dry eye after laser in situ keratomileusis［J］.Am J Ophthalmol，2001，132(1)：1-7.
［49］　BATTAT L，MACRI A，DURSUN D，PFLUGFELDER SC.Effects of laser in situ keratomileusis on tear production，clearance，and the ocular surface［J］.Ophthalmology，2001，108(7)：1230-1235.
［50］　JORDAN A，BAUM J.BASIC TEAR FLOW.Does it exist ［J］?Ophthalmology，1980，87(9)：920-930.
［51］　CHAO C，GOLEBIOWSKI B，STAPLETON F.The role of corneal innervation in LASIK-induced neuropathic dry eye［J］.Ocul Surf，2014，12(1)：32-45.
［52］　MULLER LJ，MARFURT CF，KRUSE F，TERVO TM.Corneal nerves：structure，contents and function［J］.Exp Eye Res，2003，76(5)：521-542.
［53］　NETTUNE GR，PFLUGFELDER SC.Post-LASIK tear dysfunction and dysesthesia［J］.Ocul Surf，2010，8(3)：135-145.
［54］　STAPLETON F，ALVES M，BUNYA VY，JALBERT I，LEKHANONT K，MALET F，et al.TFOS DEWS Ⅱ epidemiology report［J］.Ocul Surf，2017，15(3)：334-365.
［55］　SACK RA，BEATON A，SATHE S，MORRIS C，WILLCOX M，BOGART B.Towards a closed eye model of the pre-ocular tear layer［J］.Prog Retin Eye Res，2000，19(6)：649-668.
［56］　SCHMIDT TA，SULLIVAN DA，KNOP E，RICHARDS SM，KNOP N，LIU S，et al.Transcription，translation，and function of lubricin，a boundary lubricant，at the ocular surface［J］.JAMA Ophthalmol，2013，131(6)：766-776.
［57］　PFLUGFELDER SC，MASKIN SL，ANDERSON B，CHODOSH J，HOLLAND EJ，DE PAIVA CS，et al.A randomized，double-masked，placebo-controlled，multicenter comparison of loteprednol etabonate ophthalmic suspension，0.5%，and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance［J］.Am J Ophthalmol，2004，138(3)：444-457.
［58］　HENRIQUEZ AS，KORB DR.Meibomian glands and contact lens wear［J］.Br J Ophthalmol，1981，65(2)：108-111.
［59］　FOULKS GN，BRON AJ.Meibomian gland dysfunction：a clinical scheme for description，diagnosis，classification，and grading［J］.Ocul Surf，2003，1(3)：107-126.
［60］　MATHERS WD，LANE JA.Meibomian gland lipids，evaporation，and tear film stability［J］.Adv Exp Med Biol，1998，438：349-360.
［61］　SCHIFFMAN RM，BRADFORD R，BUNNELL B，LAI F，BERNST-EIN P，WHITCUP SW.A multi-center，double-masked，randomized，vehicle-controlled，parallel group study to evaluate the safety and efficacy of testosterone ophthalmic solution in patients with meibomian gland dysfunction［J］.Investig Ophthalmol Vis Sci，2006，47(13)：5608.
［62］　OHNISHI Y，KOHNO T.Polychlorinated biphenyls poisoning in monkey eye［J］.Invest Ophthalmol Vis Sci，1979，18(9)：981-984.
［63］　JESTER JV，NICOLAIDES N，KISS-PALVOLGYI I，SMITH RE.Meibomian gland dysfunction.Ⅱ.The role of keratinization in a rabbit model of MGD［J］.Invest Ophthalmol Vis Sci，1989，30(5)：936-945.
［64］　LAMBERT RW，SMITH RE.Hyperkeratinization in a rabbit model of meibomian gland dysfunction［J］.Am J Ophthalmol，1988，105(6)：703-705.
［65］　MCCULLEY JP，DOUGHERTY JM.Deneau DG［J］.Classificat Chron Blephar Ophthalmol，1982，89(10)：1173-1180.
［66］　GUTGESELL VJ，STERN GA，HOOD CI.Histopathology of meibomian gland dysfunction［J］.Am J Ophthalmol，1982，94(3)：383-387.
［67］　ONG BL，HODSON SA，WIGHAM T，MILLER F，LARKE JR.Evidence for keratin proteins in normal and abnormal human meibomian fluids［J］.Curr Eye Res，1991，10(12)：1113-1119.
［68］　OLAMI Y，ZAJICEK G，COGAN M，GNESSIN H，PE’ER J.Turnover and migration of meibomian gland cells in rats’ eyelids［J］.Ophthalmic Res，2001，33(3)：170-175.
［69］　BUTOVICH IA，LU H，MCMAHON A，KETELSON H，SENCHYNA M，MEADOWS D，et al.Biophysical and morphological evaluation of human normal and dry eye meibum using hot stage polarized light microscopy［J］.Invest Ophthalmol Vis Sci，2014，55(1)：87-101.
［70］　TOMLINSON A，KHANAL S.Assessment of tear film dynamics：quantification approach［J］.Ocul Surf，2005，3(2)：81-95.
［71］　HOLLY FJ，LEMP MA.Tear physiology and dry eyes［J］.Surv Ophthalmol，1977，22(2)：69-87.
［72］　MDP W，ARGüESO P，GEORGIEV GA.TFOS DEWS Ⅱ Tear Film Report［J］.Ocul Surf，2017，15(3)：366.
［73］　BUTOVICH IA.Tear film lipids［J］.Exp Eye Res，2013，117：4-27.
［74］　GEORGIEV GA.Controversies regarding the role of polar lipids in human and animal tear film lipid layer［J］.Ocul Surf，2015，13(4)：176-178.
［75］　PENG CC，CERRETANI C，LI Y，BOWERS S，SHAHSAVARANI S，LIN MC，et al.Flow evaporimeter to assess evaporative resistance of human tear-film lipid layer［J］.Ind Eng Chem Res，2014，53(47)：18130-18139.
［76］　IWATA S，LEMP MA，HOLLY FJ，DOHLMAN CH.Evaporation rate of water from the precorneal tear film and cornea in the rabbit［J］.Invest Ophthalmol，1969，8(6)：613-619.
［77］　PULT H，RIEDE-PULT BH.A new modified fluorescein strip：its repeatability and usefulness in tear film break-up time analysis［J］.Cont Lens Anterior Eye，2012，35(1)：35-38.
［78］　ZHOU L，ZHAO SZ，KOH SK，CHEN L，VAZ C，TANAVDE V，et al.In-depth analysis of the human tear proteome［J］.J Proteomics，2012，75(13)：3877-3885.
［79］　BELMONTE C，ARACIL A，ACOSTA MC，LUNA C，GALLAR J.Nerves and sensations from the eye surface［J］.Ocul Surf，2004，2(4)：248-253.
［80］　UBELS JL，GIPSON IK，SPURR-MICHAUD SJ，TISDALE AS，VAN DYKEN RE，HATTON MP.Gene expression in human accessory lacrimal glands of Wolfring［J］.Invest Ophthalmol Vis Sci，2012，53(11)：6738-6747.
［81］　CHUNG CW，TIGGES M，STONE RA.Peptidergic innervation of the primate meibomian gland［J］.Invest Ophthalmol Vis Sci，1996，37(1)：238-245.
［82］　KESSLER TL，MERCER HJ，ZIESKE JD，MCCARTHY DM，DARTT DA.Stimulation of goblet cell mucous secretion by activation of nerves in rat conjunctiva［J］.Curr Eye Res，1995，14(11)：985-992.
［83］　LEMP MA.The definition and classification of dry eye disease：report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007)［J］.Ocul Surf，2007，5(2)：75.
［84］　MOSS SE，KLEIN R，KLEIN BE.Prevalence of and risk factors for dry eye syn-drome［J］.Arch Ophthalmol，2000，118(9)：1264-1268.
［85］　PAULSEN AJ，CRUICKSHANKS KJ，FISCHER ME，HUANG GH，KLEIN BE，KLEIN R，et al.Dry eye in the beaver dam offspring study：prevalence，risk factors，and health-related quality of life［J］.Am J Ophthalmol，2014，157(4)：799-806.
［86］　SCHAUMBERG DA，BURING JE，SULLIVAN DA，DANA MR.Hormone replacement therapy and dry eye syndrome［J］.JAMA 2001，286：2114-2119.
［87］　GALOR A，FEUER W，LEE DJ，FLOREZ H，FALER AL，ZANN KL，et al.Depression，post-traumatic stress disorder，and dry eye syndrome：a study utilizing the national United States veterans affairs administrative database［J］.Am J Ophthalmol，2012，154(2)：340-346.
［88］　CREUZOT-GARCHER C.La secheresse oculaire liee aux medications systemiques［J］.J Fr Ophtalmol，2009，32(1)：64-70.
［89］　MACKIE IA，SEAL DV，PESCOD JM.Beta-adrenergic receptor blocking drugs：tear lysozyme and immunological screening for adverse reaction［J］.Br J Ophthalmol，1977，61(5)：354-359.
［90］　SAMARAWICKRAMA C，CHEW S，WATSON S.Retinoic acid and the ocular surface［J］.Surv Ophthalmol,2015，60(3)：183-195.
［91］　MATHERS WD，SHIELDS WJ，SACHDEV MS，PETROLL WM，JESTER JV.Meibomian gland morphology and tear osmolarity：changes with Accutane therapy［J］.Cornea，1991，10(4)：286-290.
［92］　BAUDOUIN C，RENARD JP，NORDMANN JP，DENIS P，LACHKAR Y，SELLEM E，et al.Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension［J］.Eur J Ophthalmol，2012,23(1):47-54.
［93］　ROSSI GC，TINELLI C，PASINETTI GM，MILANO G，BIANCHI PE.Dry eye syndrome-related quality of life in glaucoma patients［J］.Eur J Ophthalmol，2009，19(4)：572-579.
［94］　LABBE A，TERRY O，BRASNU E，VAN WENT C，BAUDOUIN C.Tear film osmolarity in patients treated for glaucoma or ocular hypertension［J］.Cornea，2012，31(9)：994-999.
［95］　LEE HJ，JUN RM，CHO MS，CHOI KR.Comparison of the ocular surface changes following the use of two different prostaglandin F2a analogues containing benzalkonium chloride or polyquad in rabbit eyes［J］.Cutan Ocul Toxicol，2015，34(3)：195202.
［96］　UCHINO M，DOGRU M，UCHINO Y，FUKAGAWA K，SHIMMURA S，TAKEBAYASHI T，et al.Japan Ministry of Health study on prevalence of dry eye disease among Japanese high school students［J］.Am J Ophthalmol，2008，146(6):925-929.
［97］　YOKOI N，YAMADA H，MIZUKUSA Y，BRON AJ，TIFFANY JM，KATO T，et al.Rheology of tear film lipid layer spread in normal and aqueous tear-deficient dry eyes［J］.Investig Ophthalmol Vis Sci，2008，49(12)：5319-5324.
［98］　SANTODOMINGO-RUBIDO J，WOLFFSOHN JS，GILMARTIN B.Changes in ocular physiology，tear film characteristics，and symptomatology with 18 months silicone hydrogel contact lens wear［J］.Optom Vis Sci，2006，83(2)：73-81.
［99］　KOJIMA T，IBRAHIM OM，WAKAMATSU T，TSUYAMA A，OGAWA J，MATSUMOTO Y，et al.The impact of contact lens wear and visual display terminal work on ocular surface and tear functions in office workers［J］.Am J Ophthalmol，2011，152(6):933-940.
［100］　NICHOLS JJ，SINNOTT LT.Tear film，contact lens，and patient-related factors associated with contact lens-related dry eye［J］.Invest Ophthalmol Vis Sci，2006，47(4)：1319-1328.
［101］　CHEN Q，WANG J，SHEN M，CUI L，CAI C，LI M，et al.Tear menisci and ocular discomfort during daily contact lens wear in symptomatic wearers［J］.Invest Ophthalmol Vis Sci，2011，52(5)：2175-2180.
［102］　AMBROSIO JR R，TERVO T，WILSON SE.LASIK-associated dry eye and neuro-trophic epitheliopathy：pathophysiology and strategies for prevention and treatment［J］.J Refract Surg，2008，24(4)：396-407.
［103］　CHO YK，KIM MS.Dry eye after cataract surgery and associated intraoperative risk factors［J］.Korean J Ophthalmol，2009，23(2)：65-73.
［104］　PRISCHMANN J，SUFYAN A，TING JY，RUFFIN C，PERKINS SW.Dry eye symptoms and chemosis following blepharoplasty：a 10-year retrospective review of 892 cases in a single-surgeon series［J］.JAMA Facial Plast Surg，2013，15(1)：39-46.
［105］　MACK WP.Complications in periocular rejuvenation［J］.Facial Plast Surg Clin N Am，2010，18(3)：435-456.
［106］　LEATHERBARROW B，SAHA K.Complications of blepharoplasty［J］.Facial Plast Surg，2013，29(4)：281-288.
［107］　SAMBURSKY R，DAVITT WF，LATKANY R，TAUBER S，STARR C，FRIEDBERG M，et al.Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye［J］.JAMA Ophthalmol，2013，131(1)：24-28.
［108］　BRON AJ，DE PAIVA CS，CHAUHAN SK，BONINI S，GABISON EE，JAIN S，et al.TFOS DEWS Ⅱ pathophysiology report［J］.Ocular Surf，2017，15(3)：438-510.
［109］　LI M，GONG L，CHAPIN WJ，ZHU M.Assessment of vision-related quality of life in dry eye patients［J］.Invest Ophthalmol Vis Sci，2012，53(9)：5722-5727.
［110］　CRAIG JP，NICHOLS KK，NICHOLS JJ，CAFFERY B，DUA HS，AKPEK EK，et al.TFOS DEWS Ⅱ Definition and Classification Report［J］.Ocul Surf，2017，15(3)：276-283.
［111］　WOLFFSOHN JS，ARITA R，CHALMERS R，DJALILIAN A，DOGRU M，DUMBLETON K，et al.TFOS DEWS Ⅱ diagnostic methodology report［J］.Ocul Surf，2017，15(3)：539-574.
［112］　DOWNIE LE，RUMNEY N，GAD A，KELLER PR，PURSLOW C，VINGRYS AJ.Comparing self-reported optometric dry eye clinical practices in Australia and the United Kingdom：is there scope for practice improvement［J］?Ophthalmic Physiol Opt，2016，36(2)：140-151.
［113］　WEGENER AR，MEYER LM，SCH ONFELD CL.Effect of viscous agents on corneal density in dry eye disease［J］.J Ocul Pharmacol Ther，2015，31(8)：504-508.
［114］　KHANDEKAR N，WILLCOX MD，SHIH S，SIMMONS P，VEHIGE J，GARRETT Q.Decrease in hyperosmotic stress-induced corneal epithelial cell apoptosis by L-carnitine［J］.Mol Vis，2013，19：1945-1956.
［115］　HUA X，SU Z，DENG R，LIN J，LI DQ，PFLUGFELDER SC.Effects of L-carnitine，erythritol and betaine on pro-inflammatory markers in primary human corneal epithelial cells exposed to hyperosmotic stress［J］.Curr Eye Res，2015，40(7)：657-667.
［116］　GOMES JAP，AZAR DT，BAUDOUIN C，EFRON N，HIRAYAMA M，HORWATH-WINTER J，et al.TFOS DEWS Ⅱ Iatrogenic report［J］.Ocul Surf，2017，15：511-518.
［117］　LI J，ZHANG X，ZHENG Q，ZHU Y，WANG H，MA H，et al.Comparative evaluation of silicone hydrogel contact lenses and autologous serum for management of sj ogren syndrome-associated dry eye［J］.Cornea，2015，34(9)：1072-1078.
［118］　ANWAR Z，WELLIK SR，GALOR A.Glaucoma therapy and ocular surface disease：current literature and recommendations［J］.Curr Opin Ophthalmol，2013，24(2)：136-143.
［119］　SCHOTANUS MP，KOETJE LR，VAN DYKEN RE，UBELS JL.Stratified corneal limbal epithelial cells are protected from UVB-induced apoptosis by elevated extracellular K［J］?Exp Eye Res，2011，93(5)：735-740.
［120］　IMAYASU M，HORI Y，CAVANAGH HD.Effects of multipurpose contact lens care solutions and their ingredients on membrane-associated mucins of human corneal epithelial cells［J］.Eye Contact Lens，2010，36(6)：361-366.
［121］　SCAFFIDI RC，KORB DR.Comparison of the efficacy of two lipid emulsion eyedrops in increasing tear film lipid layer thickness［J］.Eye Contact Lens，2007，33(1)：38-44.
［122］　MOSHIRFAR M，PIERSON K，HANAMAIKAI K，SANTIAGO-CABAN L，MUTHAPPAN V，PASSI SF.Artificial tears potpourri：a literature review［J］.Clin Ophthalmol，2014，8：1419-1433.
［123］　NICHOLS KK.The international workshop on meibomian gland dysfunction：introduction［J］.Invest Ophthalmol Vis Sci，2011，52(4)：1917-1921.
［124］　BENITEZ-DEL-CASTILLO JM.How to promote and preserve eyelid health［J］?Clin Ophthalmol，2012，6：1689-1698.
［125］　ZHAO YE，WU LP，HU L，XU JR.Association of blepharitis with Demodex：a eta-analysis［J］.Ophthalmic Epidemiol，2012，19(2)：95-102.
［126］　OUSLER G，DEVRIES DK，KARPECKI PM，CIOLINO JB.An evaluation of RetaineTM ophthalmic emulsion in the management of tear film stability and ocular urface staining in patients diagnosed with dry eye［J］.Clin Ophthalmol，2015，9：235-243.
［127］　BITTON E，LACROIX Z，LEGER S.In-vivo heat retention comparison of eyelid arming masks［J］.Cont Lens Anter Eye，2016，39(4)：311-315.
［128］　LANE SS，DUBINER HB，EPSTEIN RJ，ERNEST PH，GREINER JV，HARDTEN DR，et al.A new system，the LipiFlow，for the treatment of meibomian gland dysfunction［J］.Cornea，2012，31(4)：396-404.
［129］　AL-AMRY MA.Ocular manifestation of Ichthyosis［J］.Saudi J Ophthalmol，2016，30(1)：39-43.
［130］　LIN T，GONG L.Topical fluorometholone treatment for ocular dryness in patients with Sjgren syndrome：a randomized clinical trial in China［J］.Med Baltim，2015,94(7)：e551.
［131］　CORONEL MF，LABOMBARDA F，GONZ ALEZ SL.Neuroactive steroids，nociception and neuropathic pain：A flashback to go forward［J］.Steroids，2016，110：77-87.
［132］　BARBARINO JM，STAATZ CE，VENKATARAMANAN R，KLEIN TE，ALTMAN RB.PharmGKB summary：cyclosporine and tacrolimus pathways［J］.Pharmacogenet Genomics，2013，23(10)：563-585.
［133］　BROWN MM，BROWN GC，BROWN HC，PEET J，ROTH Z.Value-based medicine，comparative effectiveness，and cost-effectiveness analysis of topical cyclo-sporine for the treatment of dry eye syndrome［J］.Arch Ophthalmol，2009，127(2)：146-152.
［134］　SINGER DD，KENNEDY J，WITTPENN JR.Topical NSAIDs effect on corneal sensitivity［J］.Cornea，2015，34(5)：541-543.
［135］　WALSH NP，FORTES MB，RAYMOND-BARKER P，BISHOP C，OWEN J，TYE E，et al.Is whole-body hydration an important consideration in dry eye［J］?Invest Ophthalmol Vis Sci，2012，53(10)：6622-6627.
［136］　SIMOPOULOS AP.Evolutionary aspects of diet：the omega-6/omega-3 ratio and the brain［J］.Mol Neurobiol，2011，44(2)：203-215.
［137］　KAWASHIMA M，KAWAKITA T，INABA T，OKADA N，ITO M，SHIMMURA S，et al.Dietary lactoferrin alleviates age-related lacrimal gland dysfunction in mice［J］.PLoS One，2012，7：e33148.
［138］　DROUAULT-HOLOWACZ S，BIEUVELET S，BURCKEL A，RIGAL D，DUBRAY C，LICHON JL，et al.Antioxidants intake and dry eye syndrome：a crossover，placebo-controlled，randomized trial［J］.Eur J Ophthalmol，2009，19(3)：337-342.
［139］　CHHADVA P，ALEXANDER A，MCCLELLAN AL，MCMANUS KT，SEIDEN B，GALOR A.The impact of conjunctivochalasis on dry eye symptoms and signs［J］.Invest Ophthalmol Vis Sci，2015，56(5)：2867-2871.
［140］　LU R，HUANG R，LI K，ZHANG X，YANG H，QUAN Y，et al.The influence of benign essential blepharospasm on dry eye disease and ocular inflammation［J］.Am J Ophthalmol，2014，157(3)：591-597.
［141］　BAUDOUIN C，ARAGONA P，VAN SETTEN G，ROLANDO M，IRKE M，BENíTEZ DEL CASTILLO J，et al.Diagnosing the severity of dry eye：a clear and practical algorithm［J］.Br J Ophthalmol，2014，98(9)：1168-1176.
［142］　NA KS，HAN K，PARK YG，NA C，JOO CK.Depression，stress，quality of life，and dry eye disease in Korean Women：A Population-Based Study［J］.Cornea，2015，34(7)：733-738.
［143］　CRAIG JP，NICHOLS KK，AKPEK EK，CAFFERY B，DUA HS，JOO CK，et al.TFOS DEWS Ⅱ Definition and Classification report［J］.Ocul Surf，2017，15(3)：276-283.
［144］　Design and conduct of clinical trials：Report of the Clinical Trials Subcommittee of the International Dry Eye WorkShop (2007)［J］.Ocul Surf，2007，5(2)：153-162.
［145］　PINTO-FRAGA J，LPEZ-MIGUEL A，GONZLEZ-GARCA MJ，FERNNDEZ I，LPEZ-DE-LA-ROSA A，ENRQUEZ-DE-SALAMANCA A，et al.Topical fluorometholone protects the ocular surface of dry eye patients from desiccating stress［J］.Ophthalmology，2016，123(1)：141-153.
［146］　Hrobjartsson A，Gotzsche PC.Placebo interventions for all clinical conditions［J］.Cochrane Database Syst Rev，2010，(1)：CD003974.
［147］　TAUBER J，KARPECKI P，LATKANY R，LUCHS J，MARTEL J，SALL K，et al.Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease：results of the randomized phase Ⅲ OPUS-2 study［J］.Ophthalmology，2015，122(12)：2423-2431.
［148］　SULLIVAN BD，CREWS LA，S ONMEZ B，DE LA PAZ MF，COMERT E，CHAROENROOK V，et al.Clinical utility of objective tests for dry eye disease：variability over time and implications for clinical trials and disease management［J］.Cornea，2012，31(9)：1000-1008.
［149］　BAJARD A，CHAUBAUD S，CORNU C，CASTELLAN AC，MALIK S，KURBATOVA P，et al.An in silico approach helped to identify the best experimental design，population，and outcome for future randomized clinical trials［J］.J Clin Epidemiol，2016，69：125-136.
［150］　CHAO W，BELMONTE C，BENITEZ DEL CASTILLO JM，BRON AJ，DUA HS，NICHOLS KK，et al.Report of the inaugural meeting of the TFOS i(2) 1/4 initiating innovation series：targeting the unmet need for dry eye treatment［J］.Ocul Surf，2016，14(2)：264-316.
［151］　NOVACK GD.Why aren’t there more pharmacotherapies for dry eye［J］?Ocul Surf，2014，12(3)：227-230.
［152］　PEPOSE JAY S，SULLIVAN BENJAMIN D，FOULKS GARY N，LEMP MICHAEL A.The value of tear osmolarity as a metric in evaluating the response to dry eye therapy in the clinic and in clinical trials［J］.Am J Ophthalmol，2014，157(1)：4-6.
［153］　WOLFFSOHN JS，ARITA R，CHALMERS R，DJALILIAN A，DOGRU M，DUMBLETON K，et al.TFOS DEWS Ⅱ Diagnostic Methodology report［J］.Ocul Surf，2017，15(3)：539-574.

相似文献/References:

[1]姜洋 李莹 王忠海 罗岩 金玉梅.小牛血去蛋白提取物眼用凝胶对LASIK 术后角膜修复及干眼的疗效观察[J].眼科新进展,2012,32(7):000.
[2]叶芬 王春红 陈银 施宇华 黄振平.人工泪液对糖尿病干眼患者泪河的影响[J].眼科新进展,2012,32(12):000.
[3]张磊 何彦津.无眼征Graves病患者的眼表损害[J].眼科新进展,2012,32(12):000.
[4]皮百木 穆红梅 张婉婷 郑娜 李娟.老年干眼患者眼表改变及其与睑板腺功能障碍的相关性[J].眼科新进展,2013,33(6):000.
[5]张宏 马俊旗 安晓 叶向彧.围绝经期干眼患者眼表CXCR3表达与性激素的相关性分析[J].眼科新进展,2013,33(9):000.
[6]叶芬 田农 施宇华 薛春燕 黄振平.糖尿病干眼患者的波前像差分析[J].眼科新进展,2012,32(4):000.
[7]魏瑞华 郝永娜 赵少贞.自身免疫相关性干眼动物模型的研究进展[J].眼科新进展,2012,32(7):000.
[8]魏瑞华 郝永娜 边领斋 李雪 粘红 赵少贞.Sjogren综合征相关性干眼发病机制的研究进展[J].眼科新进展,2013,33(3):000.
[9]邱伟强 李学民 王薇 刘子源 张志红.泪点栓塞和人工泪液对干眼患者视功能和泪膜稳定性的影响[J].眼科新进展,2013,33(10):000.
[10]毛祖红 王乐 邵毅 张广斌 叶向彧 陈乐磊 董诺.不同方位切口对角膜神经损伤及泪膜功能影响相关性研究[J].眼科新进展,2013,33(12):000.

备注/Memo

备注/Memo:
国家自然科学基金资助（编号：81160118、81460092、81400372、81660158）；江西省远航工程（编号：2014022）；江西省自然科学基金重大项目（编号：2016-ACB21017）；江西省自然科学基金（编号：20151BAB215016）；江西省科技支撑计划项目（编号：20151BBG70223）
更新日期/Last Update: 2018-01-22